Colorectal advanced adenomas with spleen deficiency and dampness toxin syndrome after endoscopic resection
Conditions
Interventions
Experimental Group:Jianpi Lishi Jiedu Granules
Sponsors
Nanjing First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 18 and 80 years, male or female; 2.Have undergone endoscopic resection of colorectal adenoma within the past 2 weeks (cold snare resection or endoscopic mucosal resection for adenomas = 20 mm), and have been diagnosed with colorectal advanced adenoma by endoscopy and pathology; 3.Traditional Chinese Medicine (TCM) syndrome type conforms to the Spleen Deficiency and Dampness Toxin syndrome; 4.The patient is fully informed, voluntarily consents to data collection, and has signed the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Patients with diseases such as familial polyposis, inflammatory bowel disease, serrated polyposis syndrome, Peutz-Jeghers syndrome, or other hereditary polyposis syndromes; 2.Patients with long-term use of medications such as aspirin, metformin, intestinal flora regulators, folic acid, calcium preparations, and vitamin D; 3.Patients with a bleeding tendency (referring to a pathological state where hemostasis is difficult after spontaneous bleeding or minor trauma due to coagulation dysfunction or vascular structural issues) or those currently using anticoagulant medications (e.g., aspirin, clopidogrel); 4.Patients in the active phase of inflammatory bowel disease (such as ulcerative colitis, Crohn's disease, etc.), with a history of intestinal bleeding, or a history of intestinal surgery; 5.Patients with high-grade intraepithelial neoplasia involving the vascular system, lymphatic tumor thrombi, or small arteries; patients with biopsy pathology confirming suspected malignancy or established malignancy; 6.Pregnant or lactating women, or patients planning a recent pregnancy; 7.Patients with an allergic constitution or a history of allergies to multiple drugs; 8.Patients with severe heart, brain, lung, liver, kidney diseases, or mental disorders who cannot tolerate colonoscopy, treatment, and clinical intervention; 9.Patients currently participating in other clinical trials or those previously involved in trials related to this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence rate of colorectal advanced adenomas; | — |
Secondary
| Measure | Time frame |
|---|---|
| malignant transformation and interval cancer;Inflammatory Cytokines;Drug-Induced Liver Injury (DILI);Renal Impairment;Gut Microbiota;Quality of Life (KPS Scale);Gastrointestinal Function (GSRS);TCM Syndrome Efficacy; | — |
Countries
China
Contacts
Public ContactWanli Liu
Nanjing First Hospital
Outcome results
None listed